Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash from Financing Activities (2021 - 2025)

Historic Cash from Financing Activities for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to -$368000.0.

  • Lyra Therapeutics' Cash from Financing Activities fell 150000.0% to -$368000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$481000.0, marking a year-over-year decrease of 10175.21%. This contributed to the annual value of $8.5 million for FY2024, which is 8701.34% down from last year.
  • According to the latest figures from Q3 2025, Lyra Therapeutics' Cash from Financing Activities is -$368000.0, which was down 150000.0% from -$1000.0 recorded in Q4 2024.
  • Lyra Therapeutics' 5-year Cash from Financing Activities high stood at $96.5 million for Q2 2022, and its period low was -$418000.0 during Q3 2023.
  • In the last 5 years, Lyra Therapeutics' Cash from Financing Activities had a median value of $1500.0 in 2023 and averaged $10.7 million.
  • As far as peak fluctuations go, Lyra Therapeutics' Cash from Financing Activities skyrocketed by 21600000.0% in 2024, and later plummeted by 150000.0% in 2025.
  • Lyra Therapeutics' Cash from Financing Activities (Quarter) stood at -$4000.0 in 2021, then plummeted by 5800.0% to -$236000.0 in 2022, then skyrocketed by 8116.95% to $18.9 million in 2023, then plummeted by 100.01% to -$1000.0 in 2024, then tumbled by 36700.0% to -$368000.0 in 2025.
  • Its last three reported values are -$368000.0 in Q3 2025, -$1000.0 for Q4 2024, and -$23000.0 during Q3 2024.